ProKidney Corp. Class A Company Profile
NASDAQ: PROKHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ProKidney at a glance
ProKidney Corp. Class A (NASDAQ: PROK) is a Biotechnology company in the Healthcare sector headquartered in Winston-Salem, NC. ProKidney is led by Dr. Bruce Culleton M.D. and employs about 231 people. The company's shares have traded publicly since 2021.
At a market capitalization of $626.7 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001850270, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does ProKidney do?
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Business description based on the company's public filings.
Company information
- Legal name
- ProKidney Corp. Class A
- Ticker
- NASDAQ: PROK
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Bruce Culleton M.D.
- Employees
- 231
- Headquarters
- 2000 Frontis Plaza Boulevard, Winston-Salem, NC, United States
- Phone
- 336 999 7019
- Website
- prokidney.com
- IPO year
- 2021
- Market cap
- $626.72M
- SEC CIK
- 0001850270
- Latest annual report
- 10-K · Mar 18, 2026
Companies similar to ProKidney
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SGMTSagimet Biosciences Inc. Series A | 8.88 | +1.37% | $629.67M | vs PROK |
| CLYMClimb Bio Inc. | 10.71 | +0.28% | $615.14M | vs PROK |
| DBVTDBV Technologies S.A. ADR | 9.77 | -2.10% | $614.03M | vs PROK |
| SLNSilence Therapeutics Plc American Depository Share | 9.82 | -0.10% | $610.35M | vs PROK |
| FTHFaeth Therapeutics Inc. | 24.92 | -7.33% | $643.94M | vs PROK |
| ABUSArbutus Biopharma Corporation | 4.29 | -4.24% | $657.55M | vs PROK |
| ZVRAZevra Therapeutics Inc. | 11.08 | +3.26% | $657.97M | vs PROK |
| NVCTNuvectis Pharma Inc. | 20.29 | +1.30% | $662.35M | vs PROK |